title: [Adverse effects of PAD and VAD regimens in multiple myeloma patients].
abstract: The study was aimed to evaluate the adverse effects of PAD (bortezomib + adriamycin + dexamethasone) and VAD (vincristine + adriamycin + dexamethasone) as chemotherapy regimens in multiple myeloma patients. 27 and 30 patients with multiple myeloma (MM) were enrolled in PAD and VAD groups respectively. MM patients accepted 3 - 5 cycles of VAD or PAD regimens. The type, degree and occurrence time of adverse reactions during the treatment were observed. The results showed that the rash was found in two patients only in PAD group, leucocytopenia, thrombocytopenia, peripheral neuropathy, infection, fatigue, nausea, constipation, and adverse effects of cortex hormone (hypertension, glycemia, hypokalemia, hyponatremia and acne) were found in the both two groups. The thrombosis was not observed in both two groups during treatment. Although statistical analysis indicated that only the incidence of thrombocytopenia was higher in PAD group than in VAD group with statistical difference but the incidence of leucocytopenia, peripheral neuropathy and infection in PAD group were higher than those in VAD group. Rash, constipation, peripheral neuropathy could be found in the first course of chemotherapy, while the others mostly emerged after 3 courses of treatment. The main reasons for the patients who's treatment was stopped include infection and intolerable peripheral neuropathy. Although peripheral neuropathy could be found in the two groups, but the chemotherapy was stopped only in 2 patients of PAD group after 3 cycles of treatment. It is concluded that compared with conventional VAD chemotherapy, PAD may improve therapeutic effect, but it may bring more severe toxicities to the patients with multiple myeloma.
authors: Department of Heamatology, Chinese PLA General Hospital, Beijing 100853, China. zhaoyu301@yahoo.com.cn
authors: Yu
authors: Y
authors: Zhao
authors: Yu
authors: Y
authors: Jing
authors: Jian
authors: J
authors: Bo
authors: Hong-Hua
authors: HH
authors: Li
authors: Shu-Hong
authors: SH
authors: Wang
authors: Wen-Rong
authors: WR
authors: Huang
authors: Hai-Yan
authors: HY
authors: Zhu
authors: Xiao-Ping
authors: XP
authors: Han
authors: Li-Ping
authors: LP
authors: Dou
authors: Fei-Fei
authors: FF
authors: Wang
authors: Fei
authors: F
authors: Li
authors: Chun-Ji
authors: CJ
authors: Gao
authors: Quan-Shun
authors: QS
authors: Wang
authors: Li
authors: L
authors: Yu
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003907:Dexamethasone / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D011719:Pyrazines / Q000008:administration & dosage; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D014750:Vincristine; D000069286:Bortezomib; D003907:Dexamethasone; D004317:Doxorubicin